title: Changes in levels of immune activation and reconstitution markers among HIV-1-infected Africans receiving antiretroviral therapy.
abstract: OBJECTIVE
  To describe changes in immune activation and reconstitution markers among HIV-1-infected patients receiving antiretroviral therapy (ART) in Abidjan, Côte d'Ivoire.
  
  
  METHODS
  Between November 1998 and February 2001, we analyzed changes in immune activation and reconstitution markers among 52 patients. Good virologic responders (n = 26) were defined as those who had suppressed and maintained plasma viral load (VL) below the detection limit of the assay for at least 12 months. Poor virologic responders (n = 26) were defined as those with a detectable VL at 6 and 12 months after beginning ART.
  
  
  RESULTS
  Of the 26 good virologic responders, 20 (77%) were on highly active antiretroviral therapy (HAART) compared with one (4%) of the poor responders. Among the 26 good responders, baseline median levels of CD38+CD8+ T cells were elevated, but had decreased significantly at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Median levels of HLA-DR+CD8+ T cells also decreased from baseline at 6 months (P < 0.001) and at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ T cells increased steadily during the 6 and 12 months of therapy and reached levels observed among HIV-negative blood donors (P = 0.07). Among the 26 poor responders, median levels of CD38+CD8+ T cells decreased significantly at 12 months of therapy (P = 0.006), but were higher than levels in blood donors (P = 0.005). Levels of HLA-DR+CD8+ T cells decreased significantly at 12 months of therapy (P < 0.001). Levels of CD62L+CD4+ decreased over time.
  
  
  CONCLUSIONS
  Our results suggest that HAART can be successfully used in African populations with elevated baseline immune activation markers.
authors.affiliation: Projet RETRO-CI, Abidjan, Côte d'Ivoire.
authors.forename: Stéphania
authors.initials: S
authors.lastname: Koblavi-Dème
authors.forename: Matthieu
authors.initials: M
authors.lastname: Maran
authors.forename: Nguessan
authors.initials: N
authors.lastname: Kabran
authors.forename: Marie Yolande
authors.initials: MY
authors.lastname: Borget
authors.forename: Mireille
authors.initials: M
authors.lastname: Kalou
authors.forename: Luc
authors.initials: L
authors.lastname: Kestens
authors.forename: Chantal
authors.initials: C
authors.lastname: Maurice
authors.forename: Madeleine
authors.initials: M
authors.lastname: Sassan-Morokro
authors.forename: Ehounou R
authors.initials: ER
authors.lastname: Ekpini
authors.forename: Thierry H
authors.initials: TH
authors.lastname: Roels
authors.forename: Terence
authors.initials: T
authors.lastname: Chorba
authors.forename: John N
authors.initials: JN
authors.lastname: Nkengasong
mesh_terms: D036541:ADP-ribosyl Cyclase / Q000097:blood; D051997:ADP-ribosyl Cyclase 1; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D015703:Antigens, CD / Q000097:blood; D023241:Antiretroviral Therapy, Highly Active; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D007560:Cote d'Ivoire; D003906:Developing Countries; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D006684:HLA-DR Antigens / Q000097:blood; D006801:Humans; D008562:Membrane Glycoproteins; D016176:T-Lymphocyte Subsets / Q000276:immunology; D016896:Treatment Outcome; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D015703:Antigens, CD; D006684:HLA-DR Antigens; D008562:Membrane Glycoproteins; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D051997:ADP-ribosyl Cyclase 1